Novartis | NVS - Trade Debtors


Novartis reported $8.98B in Trade Debtors for its fiscal quarter ending in September of 2025.





Trade Debtors Change Date
AbbVie USD 12.77B 132M Sep/2025
Amgen USD 9.57B 1.08B Dec/2025
AstraZeneca USD 19.05B 1.49B Dec/2025
Bausch Health Companies USD 2.35B 66M Dec/2025
Biogen USD 1.85B 234M Sep/2025
Bristol-Myers Squibb USD 14.62B 485M Sep/2025
Canopy Growth CAD 26.86M 23.17M Sep/2025
Corcept Therapeutics USD 59.79M 9.84M Dec/2025
Drreddys Laboratories INR 1.41B 11.6M Dec/2025
Eli Lilly USD 19.46B 2.25B Sep/2025
Gilead Sciences USD 4.91B 182M Dec/2025
GlaxoSmithKline GBP 7.76B 545M Dec/2025
Glaxosmithkline GBP 11.16B 3.46B Sep/2025
J&J USD 17.61B 235M Sep/2025
Merck USD 12.12B 596M Sep/2025
Novartis USD 8.98B 192M Sep/2025
Novartis USD 8.98B 192M Sep/2025
Pacira USD 115.27M 901K Sep/2025
Perrigo USD 644.4M 62.2M Sep/2025
Pfizer USD 18.12B 2.02B Sep/2025
Phibro Animal Health USD 160.78M 8.67M Sep/2024
Prestige Brands USD 190.46M 8.54M Dec/2025
Roche Holding CHF 11.9B 460M Dec/2025
Sanofi EUR 397M 100M Dec/2025
Sanofi EUR 397M 186.13M Dec/2025
Supernus Pharmaceuticals USD 187.8M 16.55M Dec/2025
Zoetis USD 1.59B 49M Dec/2025